NCT00162097View on ClinicalTrials.gov

Pharmacokinetics of Efavirenz in HIV-1 Infected Subjects With Hepatic Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions
HIV InfectionsHepatic Impairment
Interventions
DRUG

efavirenz containing antiretroviral regimen

Capsule or Tablet, Oral, once daily for 2 days

DRUG

efavirenz containing antiretroviral regimen

Capsule or Tablet, Oral, once daily for 2 days

DRUG

efavirenz containing antiretroviral regimen

Capsule or Tablet, Oral, once daily for 2 days

DRUG

efavirenz containing antiretroviral regimen

Capsule or Tablet, Oral, once daily for 2 days

Trial Locations (4)

20127

Local Institution, Milan

21287

Johns Hopkins University School Of Medicine, Baltimore

23298

Virginia Commonwealth University Health Systems, Richmond

78229

Uthscsa, San Antonio

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY